OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Inclisiran: A Review in Hypercholesterolemia
James E. Frampton
American Journal of Cardiovascular Drugs (2023) Vol. 23, Iss. 2, pp. 219-230
Closed Access | Times Cited: 31
James E. Frampton
American Journal of Cardiovascular Drugs (2023) Vol. 23, Iss. 2, pp. 219-230
Closed Access | Times Cited: 31
Showing 1-25 of 31 citing articles:
Glycolipid Metabolic Disorders, Metainflammation, Oxidative Stress, and Cardiovascular Diseases: Unraveling Pathways
Enzo Pereira de Lima, Renato Cesar Moretti, Karina Torres Pomini, et al.
Biology (2024) Vol. 13, Iss. 7, pp. 519-519
Open Access | Times Cited: 24
Enzo Pereira de Lima, Renato Cesar Moretti, Karina Torres Pomini, et al.
Biology (2024) Vol. 13, Iss. 7, pp. 519-519
Open Access | Times Cited: 24
Emerging Delivery Systems for Enabling Precision Nucleic Acid Therapeutics
Xiaochun Bian, Liping Zhou, Zhiwei Luo, et al.
ACS Nano (2025)
Closed Access | Times Cited: 2
Xiaochun Bian, Liping Zhou, Zhiwei Luo, et al.
ACS Nano (2025)
Closed Access | Times Cited: 2
Navigating the landscape of RNA delivery systems in cardiovascular disease therapeutics
Paula Gil-Cabrerizo, Teresa Simón‐Yarza, Elisa Garbayo, et al.
Advanced Drug Delivery Reviews (2024) Vol. 208, pp. 115302-115302
Open Access | Times Cited: 12
Paula Gil-Cabrerizo, Teresa Simón‐Yarza, Elisa Garbayo, et al.
Advanced Drug Delivery Reviews (2024) Vol. 208, pp. 115302-115302
Open Access | Times Cited: 12
Emerging Therapeutic Targets for Acute Coronary Syndromes: Novel Advancements and Future Directions
Andreas Mitsis, Michael Myrianthefs, Stefanos Sokratous, et al.
Biomedicines (2024) Vol. 12, Iss. 8, pp. 1670-1670
Open Access | Times Cited: 5
Andreas Mitsis, Michael Myrianthefs, Stefanos Sokratous, et al.
Biomedicines (2024) Vol. 12, Iss. 8, pp. 1670-1670
Open Access | Times Cited: 5
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients Following Acute Coronary Syndromes: From Lipid Lowering and Plaque Stabilization to Improved Outcomes
Kyriakos Dimitriadis, Nikolaos Pyrpyris, Panagιotis Iliakis, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 17, pp. 5040-5040
Open Access | Times Cited: 5
Kyriakos Dimitriadis, Nikolaos Pyrpyris, Panagιotis Iliakis, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 17, pp. 5040-5040
Open Access | Times Cited: 5
Oligonucleotide therapeutics and their chemical modification strategies for clinical applications
Hyunsook Kim, Sujeong Kim, Dayoung Lee, et al.
Journal of Pharmaceutical Investigation (2024) Vol. 54, Iss. 4, pp. 415-433
Closed Access | Times Cited: 4
Hyunsook Kim, Sujeong Kim, Dayoung Lee, et al.
Journal of Pharmaceutical Investigation (2024) Vol. 54, Iss. 4, pp. 415-433
Closed Access | Times Cited: 4
Tailoring Treatment in Cardiovascular Diseases: The Role of Targeted Therapies
Razan Dankar, Jad Wehbi, Marwan M. Refaat
Pharmaceutics (2024) Vol. 16, Iss. 4, pp. 461-461
Open Access | Times Cited: 4
Razan Dankar, Jad Wehbi, Marwan M. Refaat
Pharmaceutics (2024) Vol. 16, Iss. 4, pp. 461-461
Open Access | Times Cited: 4
Active Immunization Using TRPM2 Peptide Vaccine Attenuates Atherosclerotic Progression in a Mouse Model of Atherosclerosis
Ying Fan, Yunting Zhang, Xiao Li, et al.
Vaccines (2025) Vol. 13, Iss. 3, pp. 241-241
Open Access
Ying Fan, Yunting Zhang, Xiao Li, et al.
Vaccines (2025) Vol. 13, Iss. 3, pp. 241-241
Open Access
“Are new lipid lowering agents a good option for achieving lipid goals in people living with HIV? A case report”
Raffaele Ferri, Katia Falasca, Jacopo Vecchiet, et al.
International Journal of STD & AIDS (2025)
Closed Access
Raffaele Ferri, Katia Falasca, Jacopo Vecchiet, et al.
International Journal of STD & AIDS (2025)
Closed Access
An Update on Dyslipidemia Management and Medications: A Review
Ziad A Taher, Abdulrahman A Taher, Suhaib Radi
Cureus (2024)
Open Access | Times Cited: 3
Ziad A Taher, Abdulrahman A Taher, Suhaib Radi
Cureus (2024)
Open Access | Times Cited: 3
“INCLISIRAN: EARLY LDL-C TARGET ACHIEVEMENT IN A REAL-LIFE POPULATION”
Federica Briani, Mauro Bagli, Gabriele Venturi, et al.
Atherosclerosis Plus (2025)
Open Access
Federica Briani, Mauro Bagli, Gabriele Venturi, et al.
Atherosclerosis Plus (2025)
Open Access
Advancements in Serine Protease Inhibitors: From Mechanistic Insights to Clinical Applications
Wei Yang, Mingdong Huang, Longguang Jiang
Catalysts (2024) Vol. 14, Iss. 11, pp. 787-787
Open Access | Times Cited: 3
Wei Yang, Mingdong Huang, Longguang Jiang
Catalysts (2024) Vol. 14, Iss. 11, pp. 787-787
Open Access | Times Cited: 3
Novel PCSK9 Inhibitors for Treating Cardiovascular Diseases
Ram W. Sabnis
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 4, pp. 443-444
Open Access | Times Cited: 2
Ram W. Sabnis
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 4, pp. 443-444
Open Access | Times Cited: 2
Efficacy and safety of inclisiran versus PCSK9 inhibitor versus statin plus ezetimibe therapy in hyperlipidemia: a systematic review and network meta-analysis
Suyi Zhang, Lei Sun, Xinyu Xu, et al.
BMC Cardiovascular Disorders (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Suyi Zhang, Lei Sun, Xinyu Xu, et al.
BMC Cardiovascular Disorders (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Monocytic microRNAs—Novel targets in atherosclerosis therapy
Gerhild Euler, Mariana S. Parahuleva
British Journal of Pharmacology (2024)
Open Access | Times Cited: 1
Gerhild Euler, Mariana S. Parahuleva
British Journal of Pharmacology (2024)
Open Access | Times Cited: 1
miR-181d-5p ameliorates hypercholesterolemia by targeting PCSK9
Yu Wang, Yanwen Qin, Li Fan, et al.
Journal of Endocrinology (2024) Vol. 262, Iss. 3
Open Access | Times Cited: 1
Yu Wang, Yanwen Qin, Li Fan, et al.
Journal of Endocrinology (2024) Vol. 262, Iss. 3
Open Access | Times Cited: 1
Inhibitory Effects on RNA Binding and RNase H Induction Activity of Prodrug-Type Oligodeoxynucleotides Modified with a Galactosylated Self-Immolative Linker Cleavable by β-Galactosidase
Kento Miyaji, Y. MASAKI, Kohji Seio
Bioconjugate Chemistry (2024)
Closed Access | Times Cited: 1
Kento Miyaji, Y. MASAKI, Kohji Seio
Bioconjugate Chemistry (2024)
Closed Access | Times Cited: 1
Lipoprotein(a), atherosclerosis and cardiovascular risk
E. A. Polyakova, Yu. Sh. Khalimov, E. Bazhenova, et al.
Rational Pharmacotherapy in Cardiology (2024) Vol. 20, Iss. 5, pp. 559-565
Open Access | Times Cited: 1
E. A. Polyakova, Yu. Sh. Khalimov, E. Bazhenova, et al.
Rational Pharmacotherapy in Cardiology (2024) Vol. 20, Iss. 5, pp. 559-565
Open Access | Times Cited: 1
Cardiologia Teoria e Prática - Edição XVIII
Guilherme Barroso Langoni de Freitas, MARCELO DANTAS CAMPOS, Beatriz Vasconcelos Cipola, et al.
(2024)
Closed Access | Times Cited: 1
Guilherme Barroso Langoni de Freitas, MARCELO DANTAS CAMPOS, Beatriz Vasconcelos Cipola, et al.
(2024)
Closed Access | Times Cited: 1
Lipid-Lowering Treatment and the Lipid Goals Attainment in Patients with a Very High Cardiovascular Risk
Anna E. Lis, Paulina Lis, Weronika Łowicka, et al.
Journal of Cardiovascular Development and Disease (2023) Vol. 10, Iss. 8, pp. 329-329
Open Access | Times Cited: 3
Anna E. Lis, Paulina Lis, Weronika Łowicka, et al.
Journal of Cardiovascular Development and Disease (2023) Vol. 10, Iss. 8, pp. 329-329
Open Access | Times Cited: 3
Chemical Modification and Delivery System of Small Interfering RNA Drugs★
Chen Li, Si Xiao, Jinbo Li, et al.
Acta Chimica Sinica (2023) Vol. 81, Iss. 9, pp. 1240-1240
Open Access | Times Cited: 3
Chen Li, Si Xiao, Jinbo Li, et al.
Acta Chimica Sinica (2023) Vol. 81, Iss. 9, pp. 1240-1240
Open Access | Times Cited: 3
Adverse events associated with inclisiran: a real-world disproportionality analysis based on the FAERS database
Xuyang Cai, Shaopeng Peng, Shangzhen Mu, et al.
Expert Opinion on Drug Safety (2024), pp. 1-6
Closed Access
Xuyang Cai, Shaopeng Peng, Shangzhen Mu, et al.
Expert Opinion on Drug Safety (2024), pp. 1-6
Closed Access
Natural phytochemicals as small-molecule proprotein convertase subtilisin/kexin type 9 inhibitors
Je-Wen Liou, Pei‐Yi Chen, Wan-Yun Gao, et al.
Tzu Chi Medical Journal (2024) Vol. 36, Iss. 4, pp. 360-369
Open Access
Je-Wen Liou, Pei‐Yi Chen, Wan-Yun Gao, et al.
Tzu Chi Medical Journal (2024) Vol. 36, Iss. 4, pp. 360-369
Open Access
Cajaninstilbene Acid and Its Derivative as Multi-Therapeutic Agents: A Comprehensive Review
Wen Hou, Lejun Huang, Jinyang Wang, et al.
Molecules (2024) Vol. 29, Iss. 22, pp. 5440-5440
Open Access
Wen Hou, Lejun Huang, Jinyang Wang, et al.
Molecules (2024) Vol. 29, Iss. 22, pp. 5440-5440
Open Access
Looking to the Future: Drug Delivery and Targeting in the Prophylaxis and Therapy of Severe and Chronic Diseases
Monika Schäfer‐Korting
Handbook of experimental pharmacology (2023), pp. 389-411
Closed Access | Times Cited: 1
Monika Schäfer‐Korting
Handbook of experimental pharmacology (2023), pp. 389-411
Closed Access | Times Cited: 1
